Strategies to combat COVID-19 require multiple ways to protect vulnerable people from infection. SARS-CoV-2 is an airborne pathogen and the nasal cavity is a primary target of infection. The K18-hACE2 mouse model was used to investigate the anti-SARS-CoV-2 efficacy of astodrimer sodium formulated in a mucoadhesive nasal spray. Animals received astodrimer sodium 1% nasal spray or PBS intranasally, or intranasally and intratracheally, for 7 days, and they were infected intranasally with SARS-CoV-2 after the first product administration on Day 0. Another group was infected intranasally with SARS-CoV-2 that had been pre-incubated with astodrimer sodium 1% nasal spray or PBS for 60 min before the neutralisation of test product activity. Astodrimer sodium 1% significantly reduced the viral genome copies (>99.9%) and the infectious virus (~95%) in the lung and trachea vs. PBS. The pre-incubation of SARS-CoV-2 with astodrimer sodium 1% resulted in a significant reduction in the viral genome copies (>99.9%) and the infectious virus (>99%) in the lung and trachea, and the infectious virus was not detected in the brain or liver. Astodrimer sodium 1% resulted in a significant reduction of viral genome copies in nasal secretions vs. PBS on Day 7 post-infection. A reduction in the viral shedding from the nasal cavity may result in lower virus transmission rates. Viraemia was low or undetectable in animals treated with astodrimer sodium 1% or infected with treated virus, correlating with the lack of detectable viral replication in the liver. Similarly, low virus replication in the nasal cavity after treatment with astodrimer sodium 1% potentially protected the brain from infection. Astodrimer sodium 1% significantly reduced the pro-inflammatory cytokines IL-6, IL-1α, IL-1β, TNFα and TGFβ and the chemokine MCP-1 in the serum, lung and trachea vs. PBS. Astodrimer sodium 1% nasal spray blocked or reduced SARS-CoV-2 replication and its sequelae in K18-hACE2 mice. These data indicate a potential role for the product in preventing SARS-CoV-2 infection or for reducing the severity of COVID-19.
【저자키워드】 COVID-19, SARS-CoV-2, Antiviral, astodrimer, SPL7013, dendrimer, nasal, animal model, 【초록키워드】 Treatment, Efficacy, Cytokines, sodium, IL-6, SARS-COV-2 infection, Infection, Strategy, viral shedding, lung, virus transmission, virus, anti-SARS-CoV-2, chemokine, Brain, hACE2, Nasal spray, serum, Viral, pathogen, animals, severity of COVID-19, viral replication, animal, MCP-1, virus replication, K18-hACE2 mice, pro-inflammatory cytokines, Nasal cavity, Incubation, liver, SARS-CoV-2 replication, IL-1, neutralisation, K18-hACE2, IL-1β, administration, Infectious virus, viral genome, Trachea, reduction, Post-infection, These data, secretion, product, TNFα, pro-inflammatory cytokine, TGFβ, Viraemia, IL-1α, PROTECT, blocked, was used, were infected, lack, significantly, intranasally, detectable, Day, reduced, treated, reducing, PBS, reduction in, infected intranasally, undetectable, 【제목키워드】 Formulation, challenge, K18-hACE2, spray, Effect,